Research programme: chronic obstructive pulmonary disease therapeutics - Seoul PharmaAlternative Names: SPC-702
Latest Information Update: 08 Oct 2015
At a glance
- Originator POSTECH; Seoul Pharma
- Developer Seoul Pharma
- Class Peptides
- Mechanism of Action Formyl peptide receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 08 Oct 2015 Preclinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route)